Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
entrez:
3
10
2020
pubmed:
4
10
2020
medline:
13
3
2021
Statut:
ppublish
Résumé
The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP ≥248 dB/m), while significant liver fibrosis or cirrhosis (stage ≥F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4 cell count 700 cells/μl, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.
Identifiants
pubmed: 33009010
doi: 10.1097/QAD.0000000000002650
pii: 00002030-202011010-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1915-1921Références
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328–357.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67:123–133.
Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 2017; 31:1621–1632.
Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241–248.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62:S47–S64.
Verna EC. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017; 2:211–223.
Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 2014; 210:1170–1179.
Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB. A brief clinical instrument to classify frailty in elderly people. Lancet 1999; 353:205–206.
Bauer JM, Sieber CC. Sarcopenia and frailty: a clinician's controversial point of view. Exp Gerontol 2008; 43:674–678.
Lee MJ, Kim E-H, Bae S-J, Kim GA, Park SW, Choe J, et al. Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. Gut Liver 2018; 13:67–76.
Carias S, Castellanos AL, Vilchez V, Nair R, Dela Cruz AC, Watkins J, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol 2016; 31:628–633.
Zhai Y, Xiao Q, Miao J. The relationship between NAFLD and sarcopenia in elderly patients. Can J Gastroenterol Hepatol 2018; 2018:2014–2017.
Debroy P, Lake JE, Malagoli A, Guaraldi G. Relationship between grip strength and nonalcoholic fatty liver disease in men living with HIV Referred to a metabolic clinic. J Frailty Aging 2019; 8:150–153.
Alcohol use disorders identification test (AUDIT). Epidemiol Psichiatr Soc 1998; 7:70–73.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017; 66:1022–1030.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2016; 64:1388–1402.
European AIDS Clinical Society, EACS Guidelines 2018. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html [Accessed 21 July 2019]. 2018:1--19.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735–2752.
Kamminga J, Bloch M, Vincent T, Carberry A, Brew BJ, Cysique LA. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure. J Clin Exp Neuropsychol 2017; 39:753–767.
Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 2015; 29:1633–1641.
Guaraldi G, Malagoli A, Theou O, Brothers TD, Wallace L, Torelli R, et al. Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. HIV Med 2017; 18:764–771.
Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Non-alcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of nonalcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015; 47:997–1006.
Zhang Q, Guo H, Gu H, Zhao X. Gender-associated factors for frailty and their impact on hospitalization and mortality among community- dwelling older adults: a cross-sectional population-based study. PeerJ 2018; 2018:e4326.
Blanco JR, Barrio I, Ramalle-Gómara E, Beltran MI, Ibarra V, Metola L, et al. Gender differences for frailty in HIV-infected patients on stable antiretroviral therapy and with an undetectable viral load. PLoS One 2019; 14:e0215764.
Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep 2011; 8:200–208.
Lemoine M, Lacombe K, Bastard JP, Sébire M, Fonquernie L, Valin N, et al. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients. AIDS 2017; 31:1955–1964.
Guaraldi G, Lonardo A, Maia L, Palella FJ. Metabolic concerns in aging HIV-infected persons. AIDS 2017; 31:S147–S156.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149:389–397.e10.
Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol 2017; 67:801–808.
Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67:829–846.
Kwak M-S, Kim D. Nonalcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018; 33:64–74.
Benedict M, Zhang X. Nonalcoholic fatty liver disease: an expanded review. World J Hepatol 2017; 9:715–732.
Harbell J, Terrault NA, Stock P. Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep 2013; 10:217–225.
Lazaridis N, Tsochatzis E. Current and future treatment options in nonalcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol 2017; 11:357–369.
Brodosi L, Marchignoli F, Petroni ML, Marchesini G. NASH: a glance at the landscape of pharmacological treatment. Ann Hepatol 2016; 15:673–681.